ELEV News and Press, Elevation Oncology Inc.

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer PR Newswire -- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GS...

2024-05-27 06:35:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s always a good idea to fortify your portfolio with blue-chip stocks – solid, dependable names that you can bank on to deliver each quarter. But you can’t stop there...

2024-05-10 15:00:11 ET More on the markets SPY: Growing Signs The Market Is Overbought SPY: The Shrinking Market For U.S. Companies SPY: Stronger Than Ever For the second consecutive week, investors purchase ETFs and conventional funds Earnings estima...

Elevation Oncology to Present at the Citizens JMP Life Sciences Conference PR Newswire BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therap...

2024-05-03 13:16:04 ET Summary Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment of pat...

2024-05-02 13:27:31 ET More on Elevation Oncology Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) Top 10 best performing biotech stocks of 2024 so far Read the full article on Seeking Alpha For further details see: Elevation O...

2024-05-02 10:00:43 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

2024-05-02 08:07:11 ET More on Elevation Oncology Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) Top 10 best performing biotech stocks of 2024 so far Seeking Alpha’s Quant Rating on Elevation Oncology Historical earnings d...

Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements PR Newswire -- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan ; expect to announce initial safety and efficacy data by mid-3Q 2024, wi...

2024-04-22 11:00:17 ET Summary Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promis...